Andrew Joiner, President, Chief Executive Officer and Tepha Board Member
Mr. Joiner was appointed CEO in October of 2012 and brings to Tepha 25 years of medical device experience including Sales, Marketing, General Management, and Executive Leadership. Prior to joining Tepha, Mr. Joiner was Vice President and General Manager of Commercial Operations, at Tornier, a global provider of Extremity Orthopedics from April of 2008, to January of 2012. Previous to joining Tornier, Mr. Joiner served at American Medical Systems from December of 2000 to April 2008, in various executive leadership roles including General Manager, Women’s Health. Previous to his tenure at American Medical Systems, Mr. Joiner spent ten years at U.S. Surgical.
Ian Vawter, Chief Financial Officer
Mr. Vawter is a medical device finance professional with experience in a variety of enterprises, from pre-commercial start-up to multi-national conglomerate. Joining Tepha in 2017 he brings over 20 years of experience in the medical device industry with a broad range of device experiences, ranging from capital equipment to biological implants. He has held ever increasing roles with companies such as CSA Medical, iWalk, Tissue Science Laboratories, Covidien and EDAP TMS.
John Hartnett, Executive Vice President and Chief Operating Officer
Mr. Hartnett has over 20 years of experience in medical devices, and was formerly the Director of Business Development at Boston Scientific. His experiences range from product sales, product marketing, business development, and strategic planning for a variety of medical device product ranges. He holds an M.B.A. from Boston University.
David Martin, Ph.D., Chief Scientific Officer and Senior Vice President of Research and Development
Dr. Martin is an expert on the development of medical applications with the Company’s PHA biomaterials and their manufacture, and has been with Tepha since its inception. He has over 12 years of R&D experience with the Company’s biomaterials, and previously worked at Metabolix on various aspects of PHA biochemistry, synthesis, and applications development. He completed a Ph.D. in organic chemistry at Stanford University in 1994.
Said Rizk, Chief Innovation Officer, Senior Vice President of Manufacturing and Process Development
Mr. Rizk is a leading expert in fiber and medical textiles. He joined Tepha in 2003 and brought with him over 30 years of medical device experience. At Tepha Mr. Rizk is responsible for the development and management of a state-of-the-art-manufacturing facility as well as leading Tepha’s new product development program.
Previously, Mr. Rizk was Sr. Director of Development Engineering at U.S. Surgical where he helped USS become a suture company and built pilot manufacturing of surgical needles to resolve dependency on outside sourcing. Prior to joining USS, Mr. Rizk was the Manager of Suture Development and Commercialization at Ethicon Inc. J&J where he developed absorbable and non-absorbable suture products and managed pilot manufacturing operation leading to early product launch and process transfer to permanent manufacturing sites.
Connie Garrison, Senior Vice President, Regulatory, Clinical and Quality Systems
Ms. Garrison joined Tepha in the fall of 2015, bringing with her more than 30 years of experience in medical device companies. Prior to joining Tepha, Ms. Garrison was Vice President of Regulatory Affairs at Allergan, Vice President of Regulatory, Clinical and Quality Systems at Anika, and held similar roles at Miltenyi Biotec and BioTransplant. She received her Masters of Business Administration from Barry University, graduated magna cum laude with her bachelor’s degree in Natural Sciences from Doane College, and has additional certifications in medical technology and regulatory affairs.
Lois Lombardi,Vice President, Galatea
Ms. Lombardi joined Galatea Surgical in 2015, bringing with her more than 25 years of experience in the medical device field focusing on developing and commercializing breakthrough biomedical products that help save and improve patient’s lives. Before joining Tepha, Ms. Lombardi held various leadership positions in global marketing, sales, strategic planning, product development, R&D and operations at St. Jude Medical, Abbott Vascular and Guidant Corporation. Ms. Lombardi earned a bachelor’s degree in mechanical engineer from Northeastern University and a MBA from the Peter F. Drucker School of Management at Claremont Graduate University.
Board of Directors
Richard B. Emmitt, Chairman Of The Board Of Directors, Tepha Inc.
Richard (“Dick”) Emmitt has over 40 years of experience focused on the medical device industry including investment research, investment banking, and principal investing. Mr. Emmitt is a General Partner of The Vertical Group which he co-founded in 1988. With a successful track record in all stages of venture capital and private equity investments, Mr. Emmitt is recognized as one of the medical device industry’s most successful and strategic investors. Among his former investments and BOD memberships are companies in virtually all major sectors of the medical device industry and include: American Medical Systems (acquired by Endo Pharma); ENTrigue Surgical (acquired by Arthrocare); ev3 (acquired by Covidien/Medtronic); SciMed Life Systems (acquired by Boston Scientific); Tornier (acquired by Wright Medical); Wright Medical Group (NASDAQ: WMGI) and Xomed Surgical (acquired by Medtronic). Mr. Emmitt currently serves on the Board of Directors of Biorez, Tepha Medical, MicroVascular Tissues and Monteris Medical.
Rutgers School of Business, MBA – Bucknell University, BA
Edward Giles, Director
Mr. Giles is a Special Limited Partner of The Vertical Fund, and Chairman of The Vertical Group. From 1979 through 1985, he was President of F. Eberstadt & Co., and then Vice Chairman of Eberstadt Fleming until 1988. Mr. Giles received a B.Ch.E. from Princeton University in 1957 and a S.M. (industrial management) from the Massachusetts Institute of Technology in 1959. He is also a board member of Ventana Medical Systems and Metabolix, Inc.
Anthony J. Sinskey Sc.D, Sc.D., Director
Anthony J. Sinskey, Sc.D., is a Professor of Microbiology at the Massachusetts Institute of Technology. He also holds positions as Co-Director of the Malaysia-MIT Biotechnology Partnership Program and as Faculty Director of the MIT Center for Biomedical Innovation. He conducts interdisciplinary research in metabolic engineering focusing on the fundamental physiology, biochemistry and molecular genetics of important organisms.
Professor Sinskey is well known in the biopharmaceutical industry and has been a Scientific Co-founder of several biotechnology companies, including Genzyme Corporation, Metabolix, Merrimack Pharmaceuticals, and Tepha. Dr. Sinskey has given more than 350 presentations at U.S. and International scientific meetings and congresses. He has received 31 issued patents, has made more than 30 invention disclosures and has published more than 360 scientific papers in leading peer-reviewed journals for biology, metabolic engineering, and biopolymer engineering.
His current research focuses on the genetics and biochemistry of carbon storage in biological systems including biopolymers and triacylglycerides. Investigations include studies with a variety of feedstocks to fuels, chemicals and biopolymers.
Dr. Sinskey received his undergraduate degree from the University of Illinois at Urbana-Champaign and his Sc.D. in Microbiology and Food Science from the Massachusetts Institute of Technology. His post-doctoral work was done at the Harvard School of Public Health.
Matthew Strobeck, Ph.D., Director
From June 2008 to October 2011, Dr. Strobeck was a partner, member of the management committee and member of the advisory board of Westfield Capital Management, an investment firm with approximately $15 billion in assets under management. Dr. Strobeck organized and completed the repurchase of Westfield in 2008 from Boston Private Bank, and prior to this transaction he was a member of the investment team. Dr. Strobeck received a B.S. from St. Lawrence University, a Ph.D. from the University of Cincinnati, an S.M. from the Harvard University-MIT Health Sciences Technology Program and an S.M. from the MIT Sloan School of Management.
Simon Williams, Ph.D., Director
Dr. Williams has over 20 years of experience in creating, organizing, developing, licensing, financing and managing new medical and chemical technologies from early stage research through to commercially viable products. Prior to Akeso Biomedical, Dr. Williams was the President of Tepha, Inc., where he formulated a product development strategy for a new absorbable biomaterials technology that led to FDA regulatory clearance of 17 novel medical device products over 5 years. Products developed by Tepha included CR Bard’s Phasix™ hernia repair mesh, B. Braun Surgical’s MonoMax® absorbable sutures, Tornier’s Phantom Fiber™ for ligament and tendon repair, and Galatea’s GalaFLEX® mesh for plastic and reconstructive surgery. Dr. Williams is a cofounder of the bioscience company, Metabolix (NASDAQ: MBLX), and served on the Metabolix Board of Directors from its formation in 1992 until 2006. Dr. Williams was a lecturer in organic chemistry at Manchester University in England, a visiting scientist and NATO postdoctoral fellow at M.I.T., and completed a Ph.D. in organic chemistry at Cambridge University, England. Dr. Williams is a Fellow of the Royal Society of Medicine
Martin Emerson, Director
Mr. Emerson is the President and Chief Executive Officer of Monteris Medical. Mr. Emerson has over 25 years of medical device industry experience, including CEO positions with both private and public companies. He has the leadership and market knowledge necessary to continue to grow Monteris into a world-class medical device company. Prior to joining Monteris, Marty spent eight years as the President and CEO of Galil Medical, a private company and leader in the cryoablation systems market. During his tenure, Galil’s sales increased fourfold, and the company was acquired by BTG plc in June, 2016. During the eight years leading up to Galil, he was President and CEO of American Medical Systems (AMS), a public urology and gynecology device company with sales of over $500 million. Prior to both Galil and AMS, he held various management positions, both domestic and international, with Boston Scientific Corporation and Baxter International. He currently serves on the Board of Directors for Incisive Surgical, and Tepha Medical Devices. Marty holds a B.S. degree in accounting from Marquette University.